voriconazol
J - Antiinfectives For Systemic Use -> J02 - Antimycotics For Systemic Use -> J02A - Antimycotics For Systemic Use -> J02AC - Triazole Derivatives -> J02AC03 - Voriconazole
Administration category:
Free
Medicine group:
antifungal
Brand name:
Vfend
Standard dosages
Weight | ROA | Load | Dosage | |
---|---|---|---|---|
ROA: po |
Load: 400mg |
Dosage: 200mg 2 dd |
||
ROA: iv |
Load: 6mg/kg |
Dosage: 4mg/kg 2 dd |
||
Comments:
per os: dag 1 oplaaddosis 400 mg 2 dd, intraveneus: dag 1 oplaaddosis: 6 mg/kg 2 dd |
Kidney function
ROA | GFR | Dosage | Interval | Comments |
---|---|---|---|---|
ROA: po | ||||
GFR: <50 |
Dosage: po: eerste 24 uur 400 mg 2 dd gevolgd door 200 mg 2dd. Doseren op geleide van spiegels |
|||
ROA: iv | ||||
GFR: <50 |
Dosage: iv: eerste 24 uur 6 mg/kg 2 dd gevolgd door 4 mg/kg 2 dd. Doseren op geleide van spiegels |
Notes GFR general:
De contraindicatie voor IV toediening bij nierfunctiestoornissen of nierfunctie-vervangende therapie is vervallen.
Er kan weliswaar stapeling van SBECD plaatsvinden, maar hiervan zijn geen nadelige gevolgen gezien en iv toediening kan ook bij matige nierfunctie of nierfunctievervangende therapie plaatsvinden.
Renal elimination:
2%
Dosage:
independent on kidney function
Renal function-replacement therapy
CAPD: po/iv: doseren conform GFR<50 ml/min
Hemo dialysis: po/iv: doseren conform GFR<50 ml/min
CAV / VVHD: po/iv: doseren conform GFR<50 ml/min
Interactions
Interaction with (ATC): | Expected effect: |
---|---|
Interaction with (ATC): L04AD01 - Ciclosporin |
Expected effect: verhoging spiegels ciclosporine |
Interaction with (ATC): L04AD02 - Tacrolimus |
Expected effect: verhoging spiegels tacrolimus |
Interaction with (ATC): L04AA10 - Sirolimus |
Expected effect: verhoging spiegels sirolimus |
Interaction with (ATC): A03FA02 - Cisapride |
Expected effect: toename cardiotoxiciteit |
Interaction with (ATC): R06AX12 - Terfenadine |
Expected effect: toename cardiotoxiciteit |
Interaction with (ATC): B01AA - Vitamin K Antagonists |
Expected effect: toename werking orale anticoagulantia |
Interaction with (ATC): A10B - Oral Blood Glucose Lowering Drugs |
Expected effect: versterking effect antidiabetica |
Interaction with (ATC): N03AB02 - Phenytoin |
Expected effect: verlaging plasmaconcentratie voriconazol en verhoging plasmaconcentratie fenytoine |
Interaction with (ATC): N03AF01 - Carbamazepine |
Expected effect: verlaging plasmaconcentratie voriconazol |
Interaction with (ATC): N03AA02 - Phenobarbital |
Expected effect: verlaging plasmaconcentratie voriconazol |
Interaction with (ATC): J04AB02 - Rifampicin |
Expected effect: verlaging plasmaconcentratie voriconazol |
Interaction with (ATC): J04AB04 - Rifabutin |
Expected effect: verlaging plasmaconcentratie voriconazol en verhoging plasmaconcentratie fenytoine en rifabutin |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-500392.1
Updated: 09/08/2021 - 16:03
Status: Published